- In March 2026, Locus Cell Co., Ltd. announced it had signed a Memorandum of Understanding with Charles River Laboratories to explore collaboration on CMC support, analytical testing, technical development, and related services for advanced therapy developers across Taiwan and the wider Asia-Pacific region.
- This agreement links Charles River’s global biologics testing expertise with Locus Cell’s cell and gene therapy manufacturing platforms, highlighting a potential build-out of integrated support for advanced therapies in a key growth geography.
- We’ll now examine how this potential integration of Charles River’s biologics testing with Locus Cell’s cell and gene therapy manufacturing could influence its investment narrative.
Find 54 companies with promising cash flow potential yet trading below their fair value.
Charles River Laboratories International Investment Narrative Recap
To own Charles River, you need to believe that demand for outsourced preclinical and advanced therapy services can recover despite recent earnings pressure and industry change. The Locus Cell MoU modestly reinforces the bull case around cell and gene therapy capabilities, but it does not directly change the near term catalyst of stabilizing DSA demand or the key risk from growing competition and pricing pressure across global CRO markets.
Among recent announcements, the 2026 guidance for flat to 1.5% organic revenue growth and continued earnings recovery is most relevant here. The Locus Cell MoU sits alongside that guidance as a potential incremental support for Charles River’s advanced therapy positioning in Asia Pacific, but the core question remains whether management can translate its expanding partnership network into sustained revenue growth and better margins over time.
Yet, while the Locus Cell MoU highlights opportunity in advanced therapies, investors should also be aware that pricing pressure from aggressive CRO competitors and...
Read the full narrative on Charles River Laboratories International (it's free!)
Charles River Laboratories International's narrative projects $4.4 billion revenue and $483.2 million earnings by 2028. This requires 2.8% yearly revenue growth and a $552.4 million earnings increase from -$69.2 million today.
Uncover how Charles River Laboratories International's forecasts yield a $215.73 fair value, a 40% upside to its current price.
Exploring Other Perspectives
While this MoU points to upside in advanced therapies, the most bearish analysts still saw revenues falling to about US$2.8 billion and earnings only reaching roughly US$174 million by 2028, a much harsher view than the consensus, so it is worth weighing whether this new deal could soften that pessimism or if their concerns about long term demand and profitability still resonate.
Explore 3 other fair value estimates on Charles River Laboratories International - why the stock might be worth 10% less than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Charles River Laboratories International research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Charles River Laboratories International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Charles River Laboratories International's overall financial health at a glance.
Looking For Alternative Opportunities?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com